Biowaiver for Lower Strength [Regulatives / Guidelines]

posted by wienui  – Germany, Oman, 2020-11-24 10:42 (302 d 16:51 ago) – Posting: # 22081
Views: 1,060

(edited by wienui on 2020-11-24 11:09)

Hi Vandee & Ohlbe,

As Ohlbe said, according to EMA for an additional strength biowaiver, the Amount of API(s) must be < 5% of tablet (capsule) core weight for both strengths, the BE strength and the biowaiver one.
Moreover, the Amounts of excipients are the same per strength or Only the amount of a filler is changed to account for changes in API weight.

The FDA doesn't consider this 5% rule and the requirements for an additional strength biowaiver are as following:Both EMA & FDA are asking for the Similarity of dissolution characteristics of the biowaiver strength to the strength for which bioequivalence has been demonstrated in vivo.


I hope this could help.

Cheers,
Osama

Complete thread:

Activity
 Admin contact
21,691 posts in 4,534 threads, 1,541 registered users;
online 3 (0 registered, 3 guests [including 2 identified bots]).
Forum time: Thursday 04:34 CEST (Europe/Vienna)

Learning is a lifetime process, but there comes a time
when we must stop adding and start updating.    Robert Brault

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5